Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 15/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phloyoside I SCHEMBL29426051 | 0.88 | POLB (0.55) | POLBCTDSP1STAT3MEN1KMT2A | |
| Phlomiol SCHEMBL9057941 | 0.88 | POLB (0.55) | POLBCTDSP1STAT3MEN1KMT2A | |
| SCHEMBL20476536 | 0.80 | POLB (0.52) | POLBCTDSP1STAT3MEN1KMT2A | |
| SCHEMBL29426020 | 0.80 | POLB (0.51) | POLBCTDSP1STAT3MEN1KMT2A | |
| SCHEMBL31179905 | 0.80 | POLB (0.51) | POLBCTDSP1STAT3MEN1KMT2A | |
| SCHEMBL29425813 | 0.79 | POLB (0.59) | POLBCTDSP1STAT3MEN1KMT2A | |
| SCHEMBL29425860 | 0.79 | ALDH1A1 (0.49) | POLBCTDSP1STAT3MEN1KMT2A | |
| SCHEMBL29426138 | 0.77 | MAPT (0.57) | POLBCTDSP1STAT3MEN1KMT2A | |
| Phlorigidoside C SCHEMBL29425891 | 0.77 | POLB (0.61) | POLBCTDSP1STAT3MEN1KMT2A | |
| SCHEMBL29426190 | 0.76 | STAT3 (0.49) | POLBCTDSP1STAT3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240373975-A1 | METHOD OF PROVIDING FOOT ORTHOTICS | Custom Foot Inserts Pty Ltd (AU) | 2024-11-14 | — | — | US | claimed |
| EP-4366574-A1 | METHOD OF PROVIDING FOOT ORTHOTICS | Custom Foot Inserts Pty Ltd (AU) | 2024-05-15 | — | — | EP | claimed |
| WO-2023279164-A1 | METHOD OF PROVIDING FOOT ORTHOTICS | Custom Foot Inserts Pty Ltd (AU) | 2023-01-12 | — | — | WO | claimed |
| US-20260083465-A1 | FIRST METATARSAL LATERAL RELEASE INSTRUMENT AND TECHNIQUE | TREACE MEDICAL CONCEPTS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12484917-B2 | First metatarsal lateral release instrument and technique | Treace Medical Concepts, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| CN-120078792-A | Application of sesamin in medicine with parkinsonism neuroprotection | 桂林医学院附属医院 | 2025-06-03 | — | — | CN | disclosed |
| EP-4482408-A2 | FIRST METATARSAL LATERAL RELEASE INSTRUMENT AND TECHNIQUE | Treace Medical Concepts, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240390042-A1 | Combined Intramedullary-Extramedullary Bone Stabilization and Alignment System | LUNDQUIST ANDREW D (US) | 2024-11-28 | — | — | US | disclosed |
| US-20240382568-A1 | ALKALINE PHOSPHATASE POLYPEPTIDES AND METHODS OF USE THEREOF | ALEXION PHARMACEUTICALS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240373975-A1 | METHOD OF PROVIDING FOOT ORTHOTICS | Custom Foot Inserts Pty Ltd (AU) | 2024-11-14 | — | — | US | disclosed |
| US-12083169-B2 | Alkaline phosphatase polypeptides and methods of use thereof | ALEXION PHARMACEUTICALS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230263543-A1 | FIRST METATARSAL LATERAL RELEASE INSTRUMENT AND TECHNIQUE | SLR INVESTMENT CORP. | 2023-08-24 | — | — | US | disclosed |
| US-20230129236-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE AND JOINT DISEASES | FERGUSON HORACE OSBORNE (US) | 2023-04-27 | — | — | US | disclosed |
| WO-2023279164-A1 | METHOD OF PROVIDING FOOT ORTHOTICS | Custom Foot Inserts Pty Ltd (AU) | 2023-01-12 | — | — | WO | disclosed |
| US-11517360-B2 | Method and apparatus for treating canine cruciate ligament disease | THE FOUNDRY, LLC (US) | 2022-12-06 | — | — | US | disclosed |
| CN-114982563-A | Amino acid application method for increasing sesamin content of sesamin leaves | 黑龙江八一农垦大学 | 2022-09-02 | — | — | CN | disclosed |
| US-20220265784-A1 | ALKALINE PHOSPHATASE POLYPEPTIDES AND METHODS OF USE THEREOF | ALEXION PHARMACEUTICALS, INC. | 2022-08-25 | — | — | US | disclosed |
| WO-2022115594-A2 | METHODS OF TREATING SUPERFICIAL DIGITAL FLEXOR TENDON INJURIES, DEEP AND SUPERFICIAL MUSCLE/TENDON CONTRACTURE, NAVICULAR SYNDROME, AND SUSPENSORY LIGAMENT INFLAMMATION AND INJURIES IN QUADRUPED ANIMALS | VETMED THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| CN-110646529-B | Method for detecting chemical components in reed rhizome based on UPLC-QTOF/MS | 江阴天江药业有限公司 | 2022-03-08 | — | — | CN | disclosed |
| WO-2022045385-A1 | COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR REGROWTH | 주식회사 엘지생활건강 | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083465-A1 | FIRST METATARSAL LATERAL RELEASE INSTRUMENT AND TECHNIQUE | MMP13, MMP3, MMP17 | POLB 2539/4885CTDSP1 4316/4885STAT3 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.